The Postoperative Nausea and Vomiting market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Postoperative Nausea and Vomiting: An Overview
Postoperative nausea and vomiting (PONV) is an enormous problem for patients recovering after surgery. About one-third of people experience vomiting, and half of them experience nausea. Nausea, retching, or vomiting usually occurs during the first 24–48 h after surgery in inpatients. Also, PONV is a common side effect following sedation and general anesthesia.
The consequences of PONV can include increased anxiety for future surgical procedures, increased recovery time and hospital stay, and in severe cases, aspiration pneumonia, incisional hernia or suture dehiscence, bleeding esophageal rupture, and metabolic alkalosis.
Postoperative Nausea and Vomiting (PONV) is the second most common complaint reported by the patient after the postoperative procedures. Although there are widely varying estimates on the incidence of PONV—a likely result of the diverse set of patients, surgical procedures, and chemicals used—it is often reported to be approximately 30%.
Postoperative Nausea and Vomiting Market Key Facts
The total population of PONV in the 7MM was 17,264,000+ in 2020.
As per DelveInsight, among the 7MM, the United States had the highest population of PONV in 2020 followed by Japan.
According to estimated, in 2020, the total cases of PONV included 9,939,406 cases of patients with prophylactic antiemetics: nausea and vomiting, and 2,288,058 cases without it in the United States.
Among the EU5 countries, Germany had the highest population of PONV, followed by Italy, which had a population of 404,900+, and Spain had the lowest population of PONV, i.e. 291,600+.
According to DelveInsight’s analysis, the cases of patients with prophylactic antiemetics are more in comparison to patients without antiemetics.
The Postoperative Nausea and Vomiting market size in the 7MM was found to be USD 1,934.25 Million in 2020. The United States accounts for the highest market size of PONV, in comparison to the other major markets, i.e., EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The current therapeutic landscape of PONV in the US is driven by Aloxi, Zuplenz, genetics, and several off-label therapies. But with the recent approval of Barhemsys, the market is expected to experience a change.
The Postoperative Nausea and Vomiting Market is expected to increase during the forecast period owing to the growing population of PONV patients in the 7MM and the launch of emerging therapies.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Postoperative Nausea and Vomiting market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Postoperative Nausea and Vomiting market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Postoperative Nausea and Vomiting Epidemiology
The epidemiology section covers insights about the historical and current Postoperative Nausea and Vomiting patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Postoperative Nausea and Vomiting Epidemiology Segmentation
Total Inpatient Surgeries in the 7MM
Total Postoperative Nausea and Vomiting (PONV) Cases in the 7MM
Total Number of Patients with Antiemetic Treatment (prophylactic) or Without Antiemetics Treatment in the 7MM
Postoperative Nausea and Vomiting Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Postoperative Nausea and Vomiting market or expected to get launched in the market during the study period. The analysis covers Postoperative Nausea and Vomiting market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Postoperative Nausea and Vomiting Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Postoperative Nausea and Vomiting Therapeutics Analysis
The available therapeutics treatment options in Postoperative Nausea and Vomiting (PONV) focus on the prevention of PONV. Barhemsys (formerly known as APD421 and Baremsis) was recently approved and some more emerging therapy such as CR845 and CAM2058 are under development, expected to launch in the coming years. The launch of the therapies is anticipated to transform the market dynamics.
Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/postoperative-nausea-and-vomiting-ponv-market
Some of the key companies in the Postoperative Nausea and Vomiting Market include:
And many others
Postoperative Nausea and Vomiting Therapies covered in the report include:
CR845 (difelikefalin) – CR845 which is under development by Cara Therapeutics (also known as difelikefalin) is an analgesic opioid peptide acting as a peripherally specific, highly selective agonist of the kappa opioid receptor.
CAM2058 – CAM2058, co-developed by Camurus and Braeburn, is a buprenorphine and granisetron combined subcutaneous (SC) depot formulation based on the FluidCrystal injection depot technology. The phase I clinical trial investigating pharmacokinetics (PK), pharmacodynamics (PD), and safety of CAM2058 was completed in 2017 and is under development in phase I/II.
Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/postoperative-nausea-and-vomiting-ponv-market
Table of Content
1. Key Insights
2. Executive Summary
3. Postoperative Nausea and Vomiting Competitive Intelligence Analysis
4. Postoperative Nausea and Vomiting Market Overview at a Glance
5. Postoperative Nausea and Vomiting Disease Background and Overview
6. Postoperative Nausea and Vomiting Patient Journey
7. Postoperative Nausea and Vomiting Epidemiology and Patient Population
8. Postoperative Nausea and Vomiting Treatment Algorithm, Current Treatment, and Medical Practices
9. Postoperative Nausea and Vomiting Unmet Needs
10. Key Endpoints of Postoperative Nausea and Vomiting Treatment
11. Postoperative Nausea and Vomiting Marketed Products
12. Postoperative Nausea and Vomiting Emerging Therapies
13. Postoperative Nausea and Vomiting Seven Major Market Analysis
14. Attribute Analysis
15. Postoperative Nausea and Vomiting Market Outlook (7 major markets)
16. Postoperative Nausea and Vomiting Access and Reimbursement Overview
17. KOL Views on the Postoperative Nausea and Vomiting Market.
18. Postoperative Nausea and Vomiting Market Drivers
19. Postoperative Nausea and Vomiting Market Barriers
21. DelveInsight Capabilities
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/postoperative-nausea-and-vomiting-ponv-market
Trending Healthcare Reports By DelveInsight
Fatigue is one of the common problems and debilitating symptoms in cancer patients. It is observed that a majority of patients experience some level of fatigue during their course of treatment. However, to overcome the Cancer Related Fatigue, globally several key companies are working in the therapeutics domain.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States